Are Most New Copy Number Variations (CNVs) due to increasing Paternal Age and Sperm DNA Mutations?

Madison-based NimbleGen Systems Inc., which is being acquired by Swiss pharmaceutical giant Roche, announced that the Genome Structural Variation Consortium's Copy Number Variation (CNV) Project has selected NimbleGen human CGH microarrays as the platform to conduct Phase 2 of their studies. The project aims to extend the current human genome CNV map down to a 500 bp resolution, which would be a significant improvement over the existing map released last year.